文献速递头颈部肿瘤放疗姑息放疗与转移瘤

光生物调节疗法预防头颈癌急性放射性皮炎:DERMISHEAD试验

Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial).
PubMed 文献 · Radiother Oncol · 2021-03-10

DERMISHEAD试验是一项随机安慰剂对照试验,纳入46例接受放疗(伴或不伴同步化疗)的头颈癌患者,从放疗第一天起每周两次接受光生物调节疗法(PBMT)或安慰剂,并配合机构标准皮肤护理。结果显示PBMT显著减少放疗结束时NCI-CTCAE 2-3级急性放射性皮炎,发生率为49%。结论认为PBMT是预防严重急性放射性皮炎的有效方法,支持在肿瘤放疗临床实践中实施。

要点

  • PBMT从放疗第一天起每周两次,可显著减少头颈癌患者2-3级急性放射性皮炎。
  • 放疗结束时PBMT组NCI-CTCAE 2-3级急性放射性皮炎发生率为49%。
  • 这是首项在头颈癌患者中开展的随机对照试验,支持PBMT纳入临床放疗实践。

核心结论

  • 在头颈癌患者中,PBMT是预防严重急性放射性皮炎发展的有效方法,支持在临床肿瘤放疗实践中实施PBMT。

研究设计与样本

  • 随机、安慰剂对照试验(DERMISHEAD试验),纳入46例接受放疗伴或不伴同步化疗的头颈癌患者。
  • 患者从放疗第一天起随机接受PBMT或安慰剂治疗,每周两次,并同时接受机构标准皮肤护理。

主要发现

  • PBMT显著减少NCI-CTCAE 2-3级急性放射性皮炎,放疗结束时发生率为49%。
  • 皮肤反应严重程度采用NCI-CTCAE v4.03和RISRAS评估,生活质量采用Skindex-16问卷评估。

关键数值与推荐

  • 急性放射性皮炎严重程度采用NCI-CTCAE v4.03分级。
  • 皮肤反应采用RISRAS评估,生活质量采用Skindex-16问卷评估。

临床怎么用

  • 从放疗第一天起每周两次给予PBMT,并联合机构标准皮肤护理,可降低头颈癌患者严重急性放射性皮炎的发生。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: The purpose of this study was to investigate the effectiveness of photobiomodulation therapy (PBMT) for the prevention of acute radiation dermatitis (ARD) in head and neck cancer (HNC) patients. MATERIALS AND METHODS: A randomised, placebo-controlled trial (RCT) with 46 HNC patients who underwent radiotherapy (RT) with or without concomitant chemotherapy was set up (DERMISHEAD trial). Patients were randomised to receive PBM or placebo treatments from the first day of RT (2×/week) alongside the institutional skincare. The severity of skin reactions was assessed by the National Cancer Institute-Common Terminology Criteria for Adverse Events version 4.03 (NCI-CTCAE v4.03) and the Radiotherapy-Induced Skin Reaction Assessment Scale (RISRAS). Quality of life (QoL) was evaluated using the Skindex-16 questionnaire. RESULTS: PBMT significantly reduced NCI-CTCAE grade 2-3 ARD with 49% at the end of RT. CONCLUSION: The results of the first RCT in HNC patients showed that PBMT is an effective method to prevent the development of severe ARD. These results support the implementation of PBM in the clinical oncology - radiotherapy practice.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Robijns J, Lodewijckx J, Claes S, et al. Photobiomodulation therapy for the prevention of acute radiation dermatitis in head and neck cancer patients (DERMISHEAD trial). Radiother Oncol. 2021. PMID: 33711412. doi:10.1016/j.radonc.2021.03.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。